Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Alaunos Therapeutics (TCRT) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Alaunos Therapeutics (TCRT) over the last 13 years, with Q1 2025 value amounting to 54600.0%.

  • Alaunos Therapeutics' EBITDA Margin rose 1196000000.0% to 54600.0% in Q1 2025 from the same period last year, while for Sep 2025 it was 67883.33%, marking a year-over-year increase of 1322333300.0%. This contributed to the annual value of 48120.0% for FY2024, which is 6372200000.0% up from last year.
  • As of Q1 2025, Alaunos Therapeutics' EBITDA Margin stood at 54600.0%, which was up 1196000000.0% from 18875.0% recorded in Q4 2024.
  • Alaunos Therapeutics' 5-year EBITDA Margin high stood at 283.89% for Q3 2022, and its period low was 794900.0% during Q4 2023.
  • Over the past 5 years, Alaunos Therapeutics' median EBITDA Margin value was 66031.82% (recorded in 2025), while the average stood at 190717.45%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first crashed by 2000000000bps in 2023, then surged by 2000000000bps in 2024.
  • Quarter analysis of 5 years shows Alaunos Therapeutics' EBITDA Margin stood at 552550.0% in 2021, then skyrocketed by 86bps to 77463.64% in 2022, then crashed by -926bps to 794900.0% in 2023, then soared by 98bps to 18875.0% in 2024, then tumbled by -189bps to 54600.0% in 2025.
  • Its EBITDA Margin was 54600.0% in Q1 2025, compared to 18875.0% in Q4 2024 and 29150.0% in Q2 2024.